Eurofins Biomnis code

BCR

Specialty

Genetics

Clinical significance

Chronic Myeloid Leukaemia (CML) is classified by the WHO as a Myeloproliferative Neoplasia (MPN). The associated diagnostic cytogenetic abnormality is the translocation t(9;22)(q34;q11) or Philadelphia chromosome. The molecular equivalent is the BCR-ABL fusion transcript. The molecular biology test (RT-PCR and multiplex PCR) offered at the Eurofins Biomnis laboratory allows the detection of all BCR-ABL fusion transcripts: M, m, µ and nano BCR-ABL. This is a QUALITATIVE assay for the BCR-ABL transcript. This analysis can be completed by a QUANTITATIVE BCR-ABL assay, in particular for the follow-up of CML under ITK (BCRQ assay - information available on the analysis reference). We also offer cytogenetic analysis in the laboratory: haematological karyotype (MOHC1) and haematological BCR-ABL FISH (MOHC2). In the context of acute leukaemia (ALL and AML), the screening for the BCR-ABL fusion transcript can also be performed with this technique.

Preanalytics

• Whole blood on PAX gene tube : frozen 1 x 4 ml EDTA whole blood : ambient

• A tube specifically for this analysis : Yes

Further information

Use the specific request form B8-INTGB: Malignant blood disorders
4 days stability

Specific equipment available

• K10 : PAXgene tube

Documents to download

• Specific request form B8-INTGB
• DS2-INTFR - Pathological diagnosis and follow up of patients with Chronic Myeloid Neoplasms
• Protocol(K10P-INTGB)

Methodology

One-step real-time RT-PCR. Detection of 18 BCR fusion transcripts:: ABL (e1a2, e1a3, e4a2, e4a3, e6a2, e6a3, e8a2, e8a3, e13a2 (b2a2), e13a3 (b2a3), e14a2 (b3a2), e14a3 (b3a3), e16a2, e16a3, e18a2, e18a3, e19a2, e19a3) without discrimination. Detection of BCR::ABL fusion transcripts e1a2, e13a2 (b2a2), e14a2 (b3a2), e1a3, e13a3 (b2a3), e14a3 (b3a3), e19a2, e19a3 with discrimination. For rare transcripts, verification by Sanger sequencing.

Turnaround time

18 days